Cancer Letters
Volume 227, Issue 1 , Pages 9-23 , 8 September 2005

Antitumor activity of HER-2 inhibitors

Received 2 November 2004 ,Accepted 7 November 2004.

References 

  1. Olayioye MA, Neve RN, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. Eur. Mol. Biol. Org. J. 2000;19:3159–3167
  2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2001;2:127–137
  3. Plowman GD, Culouscou JM, Whitney GS, Green JM, Carlton GW, Foy L, et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl. Acad. Sci. USA. 1993;90:1746–1750
  4. Hynes NE, Stern DF. The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta. 1994;1198:165–184
  5. Hazan R, Margolis B, Dombalagian M, Ullrich A, Zilberstein A, Schlessinger J. Identification of autophophorylation sites on HER2/neu. Cell Growth Differ. 1989;1:3–7
  6. Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997;15:1–8
  7. Hung MC, Lau YK. Basic science of Her-2/neu: a review. Semin. Oncol. 1999;26:51–59
  8. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 1998;20:41–48
  9. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of EGF domains for ErbB receptors. Fed. Eur. Biochem. Soc. Lett. 1999;447:227–231
  10. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 1996;16:5276–5287
  11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756–760
  12. Allen LF, Leneham PF, Eiseman IA, Elliot WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin. Oncol. 2002;29(Suppl. 11):11–21
  13. Earp HS, Dawson TL, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat. 1995;35:115–132
  14. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  15. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  16. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–428
  17. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, et al. The HER-2/neu gene and protein in breast cancer: biomarker and target of therapy. Oncologist. 2003;8:307–325
  18. Agus DB, Bunn PA, Franklin W, Garcia M, Ozols RF. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin. Oncol. 2000;27:53–63
  19. Scheurle D, Jahanzeb M, Aronsohn RS, Watzek L, Narayanan R. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Herceptest. Anticancer Res. 2000;20:2091–2096
  20. Cox G, Vyberg M, Melgaard B, Askaa J, Oster A, O'Byrne KJ. Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. Int. J. Cancer. 2001;92:480–483
  21. Koeppen HKW, Wright BD, Burt AD, Quirke P, McNicol AM, Dybdal NO, et al. Overexpression of HER2/neu in solid tumours: an immunohistochemical survey. Histopathology. 2001;38:96–104
  22. Bunn PA, Helfrich B, Soriano AF, Franklin WA, Varella-Garcia M, Hirsch FR, et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 2001;7:3239–3250
  23. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br. J. Cancer. 2002;86:1449–1456
  24. Osman I, Scher HI, Drobnjak M, Verbel D, Morris M, Agus D, et al. HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 2001;7:2643–2647
  25. Calvo BF, Levine AM, Marcos M, Collins QF, Iacocca MV, Caskey LS, et al. Human epidermal receptor-2 expression in prostate cancer. Clin. Cancer Res. 2003;9:1087–1097
  26. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am. J. Clin. Pathol. 2001;116:234–239
  27. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy. The Fourth Annual Joseph H. Burchenal American Association for Cancer Research Clinical Research Award Lecture. Clin. Cancer Res. 2000;6:747–753
  28. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur. J. Cancer. 2004;40:1292–1301
  29. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 2003;21:2787–2799
  30. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 2003;22:1012
  31. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol. Ther. 1999;82:207–218
  32. Morin MJ. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents. Oncogene. 2000;19:6574–6583
  33. Drucker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1:31–36
  34. Huang S, Armstrong E, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64:5355–5362
  35. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749–5754
  36. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J.Clin. Oncol. 2003;21:2237–2246
  37. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. J. Am. Med. Assoc. 2003;290:2149–2158
  38. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER-2-driven signaling and suppresses the growth of HER-2-overexpressing tumor cells. Cancer Res. 2001;61:7184–7188
  39. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER-1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER-2/neu (ErbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887–8895
  40. Arteaga CL, Ramsey TT, Shawver LK, Guyer CA. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site. J. Biol. Chem. 1997;272:23247–23254
  41. Normanno N, Maiello MR, de Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?. J. Cell. Physiol. 2002;194:13–19
  42. Moyer JD, Barbacci EG, Iwata KK, Arnold L, Boman B, Cunningham A, et al. Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997;57:4838–4848
  43. Pollack VA, Savage DM, Baker DA, Tsaparikos KE, Sloan DE, Moyer JD, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 1999;291:739–748
  44. Schaefer GM, Carroll S, Akita RW. The HER-2 tyrosine kinase is a direct target of erlotinib (Tarceva), a potent inhibitor of EGFR/HER-1 kinase. Proc. Am. Assoc. Cancer Res. 2004;45:2424
  45. Shepard FA, Periera J, Ciuleanu TE, Tan EH, Hirsh V, Thongprasert S, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J. Clin. Oncol. 2004;22(Suppl. 14S):7022
  46. Wissner A, Berger DM, Boschelli DH, Floyd MB, Greenberger LM, Gruber BC, et al. 4-anilino-6,7-dialkoxyquinoline-3-carbonitrile inhibitors of epidermal growth factor receptor kinase and their bioisosteric relationship to the 4-anilino-6,7-dialkoxyquinazoline inhibitors. J. Med. Chem. 2000;43:3244–3256
  47. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000;6:1024–1028
  48. Wissner A, Overbeek E, Reich MF, Floyd MB, Johnson BD, Mamuya N, et al. Synthesis and structure–activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of orally active irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 2003;46:49–63
  49. Greenberger LM, Discafani C, Wang Y-F, Tsou H-R, Overbeek EG, Nilakantan R, et al. EKB-569: a new irreversible inhibitor of epidermal growth factor receptor tyrosine kinase for the treatment of cancer. Clin. Cancer Res. 2000;6:4544s
  50. M. Hidalgo, C. Erlichman, E.K. Rowinsky, J. Koepp-Norris, K. Jensen, J. Boni, et al., Phase I trial of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor (EGFR), in patients with advanced solid tumors. American Society of Clinical Oncology Annual Meeting, Orlando, FL, 2002, Abstract 65.
  51. Casado E, Folprecht G, Paz-Ares L, Rojo F, Kohne CH, Cortes-Funes H, et al. A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination wth F-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC). J. Clin. Oncol. 2004;22(Suppl. 14S):3543
  52. Tejpar S, Van Cutsem E, Machover D, Soulie P, Ulusakarya A, Laurent S, et al. Phase 1/2a study of EKB-569, an irreversible inhibitor of epidermal growth factor receptor, in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-4) in patients with advanced colorectal cancer (CRC). J. Clin. Oncol. 2004;22(Suppl. 14S):3579
  53. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 1991;11:117–127
  54. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol. 1999;26:60–70
  55. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 1999;21:309–318
  56. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999;17:2639–2648
  57. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of HER-2-overexpressing metastatic breast cancer. J. Clin. Oncol. 2002;20:719–726
  58. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N. Engl. J. Med. 2001;344:783–792
  59. Mass RD. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin. Oncol. 2000;27(Suppl. 11):46–52
  60. Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann. Oncol. 2004;15:19–27
  61. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J. Clin. Oncol. 2004;22:1180–1187
  62. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, et al. The use of tratuzumab in the treatment of hormone-refractory prostate cancer. Prostate. 2004;60:332–337
  63. Lara PN, Chee KG, Longmate J, Ruel C, Meyers FJ, Gray CR, et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma. Cancer. 2004;100:2125–2131
  64. Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI. Down-modulation of an oncogenic protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell. 1985;41:695–706
  65. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 1989;9:1165–1172
  66. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001;61:4744–4749
  67. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy for solid tumors. Am. J. Pathol. 1997;151:1523–1530
  68. Izumi Y, Xu L, diTomaso E, Fukumura D, Jain RK. Herceptin acts as an anti-angiogenic cocktail. Nature. 2002;416:279–280
  69. Pack SD, Alper OM, Stromberg K, Augustus M, Ozdemirli M, Miermont AM, et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res. 2004;64:789–794
  70. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 1993;37:255–263
  71. Motoyama AB, Hynes NE, Lane HA. The efficacy of erbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002;62:3151–3158
  72. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4132–4141
  73. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004;6:117–127
  74. Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW, et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21:6255–6263
  75. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacance PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2002;2:127–137
  76. Rabindran SK, Discafani CM, Rosfjord EC, Baxter M, Floyd MB, Golas J, et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 2004;64:3958–3964
  77. Baselga J. Combined anti-EGFR receptor and anti HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing. Ann. Oncol. 2002;13:8–9
  78. Britten CD, Pegram M, Rosen PP, Finn RS, Wax A, Bosserman L, et al. Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ breast cancer. J. Clin. Oncol. 2004;22(Suppl. 14S):3045
  79. Normanno N, Campiglio M, de Luca A, Somenzi G, Maiello M, Ciardello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 2002;13:65–72
  80. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317–328
  81. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramsinghe D. Inhibition of ligand-mediated HER-2 activation in androgen-independent prostate cancer. Cancer Res. 2002;62:5485–5488
  82. Bossenmaier B, Hasmann M, Koll H, Fiebig HH, Akita RW, Sliwkowski MX, et al. Presence of HER-2/HER-3 heterodimers perdict antitumor effects of pertuzumab (Omnitarg) in different human xenograft models. Proc. Am. Assoc. Cancer Res. 2004;45:5342
  83. Nahta R, Hung M-C, Esteva FJ. The HER-2 targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004;64:2343–2346
  84. Agus DB, Gordon M, Taylor C, Natale RB, Karlan B, Mendelson D, et al. Clinical activity in a phase I trial of HER-2 targeted rhuMab 2C4 (pertuzumab) in patients with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol. 2003;22:771
  85. Allison DE, Malik M, Qureshi F, Baker D, Kelsey S, Fyfe G, et al. Pharmacokinetics of HER-2-targeted rhuMab 2C4 (pertuzumab) in patients with advanced solid malignancies: phase Ia results. Proc. Am. Soc. Clin. Oncol. 2004;22:790
  86. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA. 1998;95:12022–12027
  87. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan erbB tyrosine kinase inhibitor. Semin. Oncol. 2001;28:80–85
  88. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, et al. Drug-induced ubiquitinylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. Eur. Mol. Biol. Org. J. 2002;21:2407–2417
  89. Nelson JM, Fry DW. Akt, MAPK (Erk 1/2) and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem. 2001;276:14842–14847
  90. Murakami M, Sasaki T, Yamasaki S, Kuwahara K, Miyata H, Chayama K. Induction of apoptosis by ionizing radiation and CI-1033 in HuCCT cells. Biochem. Biophys. Res. Commun. 2004;319:114–119
  91. Vincent PW, Patmore SJ, Atkinson BE, Bridges AJ, Kirkish LS, Dudeck RC, et al. Optimal in vivo treatment schedule for the novel EGF receptor family tyrosine kinase inhibitor, PD183805, correlates with the inhibition of receptor tyrosine phosphorylation. Proc. Am. Assoc. Cancer Res. 1999;40:776
  92. Allen LF, Eiseman IA, Fry DW, Lenehan PF. CI-1033, an irreversible pan ErbB receptor inhibitor and its potential application for the treatment of breast cancer. Semin. Oncol. 2003;30:
  93. Simon GR, Olson S, Garrett CR, Eiseman I, Langevin M, Mahany JJ, et al. Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors. J. Clin. Oncol. 2004;22:3057
  94. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of normal human and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001;1:85–94
  95. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, et al. A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib); relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004;64:6652–6659
  96. Tansik RL, Singer SC, Knapp SL, Rhodes N, Gilmer TM, Dev IK. Synergistic induction of apoptosis between GW572016 and inhibitors of phosphatidylinositol-3 kinase/AKT pathway. Proc. Am. Assoc. Cancer Res. 2004;45:4661
  97. Mullin RJ, Murray DM, Onori JA, Keith BR. Xenograft response to combination therapy with the ErbB1–ErbB2 tyrosine kinase inhibitor GW572016. Proc. Am. Assoc. Cancer Res. 2004;45:3823
  98. Minami H, Nakagawa K, Kawada K, Mukai H, Tahara M, Kurata T, et al. A phase I study of GW572016 in patients with solid tumors. J. Clin. Oncol. 2004;22(Suppl. 14S):3048
  99. Versola M, Burris HA, Jones S, Wilding G, Taylor C, Pandite L, et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. J. Clin. Oncol. 2004;22(Suppl. 14S):3047
  100. Pandite L, Burris HA, Jones S, Wilding G, Taylor C, Versola MJ, et al. A safety, tolerability, and pharmacokinetic (PK) study of GW572016 in patients with solid tumors. J. Clin. Oncol. 2004;22(Suppl. 14S):3179
  101. Spector N, Xia W, Burris HA, Hurwitz H, Dees C, Dowlati A, et al. Modulation of tumor growth and survival pathways in cancer patients treated with GW572016. J. Clin. Oncol. 2004;22(Suppl. 14S):3003
  102. Dees EC, Burris H, Hurwitz H, Dowlati A, Smith D, Koch K, et al. Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. J. Clin. Oncol. 2004;22(Suppl. 14S):3188
  103. Blackwell KL, Kaplan EH, Franco SX, Marcom PK, Maleski JE, Sorensen MJ, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 2004;22(Suppl. 14S):3006
  104. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med. Res. Rev. 2001;21:499–512
  105. Mellinghof IK, Tran C, Sawyers CL. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 2002;62:5254–5259
  106. Solorzano CC, Baker CH, Tsan R, Traxler P, Cohen P, Buchdunger E, et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin. Cancer Res. 2001;7:2563–2572
  107. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002;62:1996–2003
  108. Hoekstra R, Dumez H, Van Oosterom AT, Sizer KC, Ravera C, Vaidyanathan S, et al. A phase I and pharmacogical study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally in a two weeks on, two weeks off scheme to patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 2002;43:340
  109. Murren JR, Papadimitrakopoulou VA, Sizer KC, Vaidyanathan S, Ravera C, Abbruzzese JL. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Assoc. Cancer Res. 2002;43:377
  110. Dumez H, Hoekstra R, Eskens F, Sizer K, Vaidyanathan S, Ravera C, et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGF) tyrosine kinase inhibitor, administered orally 3 times a week to patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 2002;43:341
  111. Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, et al. AEE788: a dual family epidermal growth factor receptor/ErbB and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2004;64:4931–4941
  112. Barbacci EG, Pustilnik LR, Rossi AMK, Emerson E, Miller PE, Boscoe BP, et al. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells. Cancer Res. 2003;63:4450–4459
  113. Finn RS, Wilson CA, Chen J, Glaspy P, Dering J, Cook A, et al. Biological effects of CP-724,714, a selective HER-2/neu kinase inhibitor, on breast cancer cells with variable expression of EGFR and HER-2. Proc. Am. Assoc. Cancer Res. 2004;45:4556
  114. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953–962
  115. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature. 1995;378:394–398
  116. Woldeyesus MT, Britsch S, Reithmacher D, Xu L, Sonnenberg-Reithmacher E, Abou-Rebyeh F, et al. Peripheral nervous system defects in erbB2 mutants following genetic rescue of heart development. Genes Dev. 1999;13:2538–2548
  117. Britsch S, Kirchhoff S, Theuring F, Brinkmann V, Birchmeier C, Reithmacher D. The ErbB2 and ErbB3 receptors and their ligand, neuregulin-1, are essential for development of the sympathetic nervous system. Genes Dev. 1998;12:1825–1836
  118. Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc. Med. 2003;13:80–86
  119. Gassman M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature. 1995;378:390–394
  120. Meyer D, Birchmeier C. Multiple essential functions of neuregulin in development. Nature. 1995;378:386–390
  121. Erickson SL, O'Shea KS, Ghaboozi N, Loverro L, Frantz G, Bauer M, et al. ErbB3 is required for normal cerebellar and cardiac development: a comparison with ErbB2-and heregulin-deficient mice. Development. 1997;124:4999–5011
  122. Tripathy D, Slamon DJ, Cobleigh MA, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 2004;22:1063–1070
  123. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 2002;20:1215–1221
  124. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat. Med. 2002;8:459–465
  125. Ozcelik C, Erdmann B, Pilz B, Wettsschureck N, Britsch S, Hubne N, et al. Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. Proc. Natl. Acad. Sci. USA. 2002;99:8880–8885
  126. Kaplan EH, Jones CM, Berger MS. A phase II, open-label, multicenter study of GW572016 in patients with trasuzumab refractory breast cancer. Proc. Am. Soc. Clin. Oncol. 2003;22:981
  127. Herbst RS, Maddox A-M, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 2002;20:3815–3825
  128. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 2001;19:3267–3279
  129. Albanell J, Rojo F, Averbuch SD, Feyereislova A, Mascaro JM, Herbst RS, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 2002;20:110–124
  130. Nunes M, Shi C, Greenberger LM. Phosphorylation of extracellular signal-regulated kinase 1 and 2, protein kinase B, and signal transducer and activator of transcription 3 are differentially inhibited by an epidermal growth factor receptor inhibitor, EKB-569, in tumor cell and normal human keratinocytes. Mol. Cancer Ther. 2004;3:21–27
  131. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist. 2003;8:303–306
  132. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004;350:2129–2139
  133. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  134. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167
  135. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA. 2004;101:13306–13311
  136. Dancey JE. Predictive factors for epidermal growth factor receptor inhibitors. The bull's-eye hits the arrow. Cancer Cell. 2004;5:411–415
  137. Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 2000;20:3210–3223
  138. Arteaga CL. Selecting the right patient for tumor therapy. Nat. Med. 2004;10:577–578
  139. Cancer Genome Project and Collaborative Group. Intragenic ErbB2 kinase mutations in tumours. Nature. 2004;431:525–526
  140. Christensen JG, Schreck RE, Chan E, Wang X, Yang C, Liu LH, et al. High levels of HER-2 expresion alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin. Cancer Res. 2001;7:4230–4238
  141. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti HER-2 mAb 4D5 induced growth inhibition by a human–mouse chimeric anti-EGF receptor mAb C225. Oncogene. 1999;18:731–738
  142. Kuwada SK, Scaife CL, Kuang J, Li X, Wong RF, Florell SR, et al. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells. Int. J. Cancer. 2004;109:291–301
  143. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001;93:1852–1857
  144. Camirand A, Lu Y, Pollak M. Co-targeting HER-2/ErbB-2 and insulin-like growth factor-I receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit. 2002;8:BR521–BR526
  145. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA. 2003;100:8933–8938
  146. Lenferink AEG, Busse D, Flanagan WM, Yakes FM, Arteaga CL. ErbB2/neu kinase modulates cellular p27kip1 and cyclin D1 through multiple signaling pathways. Cancer Res. 2001;61:6583–6591
  147. Shi Q-B, Solit D, Basso A, Moasser MM. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidyl 3′ kinase/Akt pathway signaling. Clin. Cancer Res. 2003;9:4340–4346
  148. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411:1017–1021
  149. Nahta R, Inglehart JD, Kempkes B, Schmidt EV. Rate-limiting effects of cyclin D1 in transformation by ErbB2 predicts synergy between Herceptin and flavopiridol. Cancer Res. 2002;62:2267–2271
  150. Yang H-Y, Zhou BP, Hung M-C, Lee M-H. Oncogenic signals of HER-2/neu in regulating the stability of the cyclin-dependent kinase inhibitor p27. J. Biol. Chem. 2000;275:24735–24739
  151. Muraoka RS, Lenferink AEG, Law B, Hamilton E, Brantley DM, Roebuck LR, et al. ErbB2/neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell. Biol. 2002;22:2204–2219
  152. Nahta R, Takahashi T, Ueno NT, Hung M-C, Esteva FJ. p27kip1 down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. 2004;64:3981–3986
  153. Yakes FM, Carter MB, Bakin AV, Arteaga CL. Oncogene-activated Akt directly phosphorylates the cyclin-dependent kinase (Cdk) inhibitor p27 kip1 and mediates cell cycle progression. Proc. Am. Assoc. Cancer Res. 2001;42:1393
  154. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trantuzumab, or tamoxifen in breast cancer cells. Mol. Cancer Ther. 2002;1:707–717
  155. Jani JP, Barbacci G, Bhattacharya S, Campbell M, Coleman K, Cox E, et al. CP-724714, a novel erbB2 receptor tyrosine kinase inhibitor for cancer therapy. Proc. Am. Assoc. Cancer Res. 2004;45:4637

PII: S0304-3835(04)00874-2

doi: 10.1016/j.canlet.2004.11.015

Cancer Letters
Volume 227, Issue 1 , Pages 9-23 , 8 September 2005

Article Tools